Regulatory framework in Pakistan: situation analysis of medicine quality and future recommendations.
Huma RasheedLudwig HoelleinKhalid Saeed BukhariGerhard BringmannPublished in: Journal of pharmaceutical policy and practice (2019)
The case reports, investigations, and general data listed for Pakistan suggest the need of strengthening regulatory systems for premises and GMP inspections, analytical laboratories, as well as an overall capacity building in the field of unravelling and controlling substandard and falsified medicines. It is proposed that well-planned and properly funded studies need to be carried out for collecting critical statistics regarding the prevalence of substandard and falsified medicines in Pakistan.